Clinical trials: Heart Diseases
Atrial Fibrillation
Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)
The primary objective of this study is to: Assess whether the addition of dronedarone to existing conventional rate control therapy leads to a reduced ventricular rate after 1 week in patients with a high Heart Rate (HR) at rest…
- Trial name
- AFRODITE (NCT01047566)
- Testing
- Dronedarone, Beta blocker or calcium antagonist or digoxin
- Where
- Netherlands
- Volunteers
- 183 people
- Sponsor
- Sanofi
Ventricular Fibrillation, Ventricular Tachycardia
Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function
Re-hospitalizations or deaths by worsening heart failure are often preceded by distinct trends of clinical parameters such as atrial or ventricular arrhythmia, activity, heart rate variability, or ventricular ectopy.
- Conditions
- Ventricular Fibrillation, Ventricular Tachycardia, Congestive Heart Failure
- Trial name
- IN-TIME (NCT00538356)
- Testing
- ICD or CRT-D with Home Monitoring feature deactivated, ICD or CRT-D with Home Monitoring feature activated
- Where
- 39 sites in Australia, Austria and 5 more
- Volunteers
- 720 people
- Sponsor
- Biotronik SE & Co. KG
Severe Aortic Stenosis
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement
The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted high risk for aortic valve surgery and/or…
- Trial name
- NCT01240902
- Testing
- Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR)
- Where
- 45 sites in United States
- Volunteers
- 1,453 people
- Sponsor
- Medtronic Cardiovascular
Patent Foramen Ovale
Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism
The primary objective of this study is to demonstrate the safety of the PFX Closure System when utilized for patients with patent foramen ovale (PFO) suffering from cryptogenic stroke, transient ischemic attacks or paradoxical…
- Trial name
- NCT00196027
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cierra
Ischemic Heart Disease
Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography
The purpose of this study is to verify the efficiency of the HyperQ technology compared with standard ECG analysis in detecting exercise induced ischemia in women who are referred to coronary angiography.
- Trial name
- NCT00850486
- Testing
- Exercise test with HyperQ technology
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- BSP Biological Signal Processing Ltd.
Chest Pain, Coronary Artery Disease
A Registry to Evaluate Patterns of Care Associated With the Use of Corus CAD (or ASGES) in Primary Care Settings
The PRESET Registry--A Registry to Evaluate Patterns of Care Associated With the Use of Corus CAD (Age/Sex/Gene Expression score - ASGES) in Real World Clinical Care Settings (PRESET)--was designed as an observational…
- Conditions
- Chest Pain, Coronary Artery Disease, Cardiovascular Diseases, Coronary Heart Disease
- Trial name
- PRESET (NCT01677156)
- Testing
- CORUS CAD (ASGES)
- Where
- 13 sites in United States
- Volunteers
- 713 people, healthy volunteers welcome
- Sponsor
- CardioDx
Patent Ductus Arteriosus
Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
This retrospective and prospective, multicenter, international post marketing follow up study evaluates the safety and efficacy of the Occlutech® PDA Occluder, delivered using the Occlutech Occlusions Pusher (OOP), in subjects…
- Trial name
- NCT05264753
- Testing
- Occlutech® PDA Occluder
- Where
- 15 sites in Canada, France and 7 more
- Volunteers
- 255 people
- Sponsor
- Occlutech International AB
Coronary Artery Disease, Coronary Disease
The INVADER™ Percutaneous Transluminal Coronary Angioplasty (PTCA) Post Market Clinical Follow-up (PMCF) Study
The aim of the present observational study is to collect clinical data on the non-implantable medical device INVADER™ PTCA in the daily use in an unselected population.
- Conditions
- Coronary Artery Disease, Coronary Disease, Vascular Diseases
- Trial name
- NCT05904951
- Testing
- INVADER™ PTCA Balloon Dilatation Catheter
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Alvimedica
Heart Failure
Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure
This study assess the safety/tolerability, PK/PD of LCZ696 in patients with stable heart failure.
- Trial name
- NCT00913653
- Testing
- LCZ696
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt
This is a multi-center, single-blind, randomized, active-controlled, clinical trial in Percutaneous Coronary Intervention (PCI) subjects.
- Trial name
- HARMONEE (NCT02073565)
- Testing
- OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
- Where
- 50 sites in United States, Japan
- Volunteers
- 572 people
- Sponsor
- OrbusNeich
Heart Failure
CCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF)
The primary objective of this study is to evaluate the impact of Cardiac Contractility Modulation (CCM) therapy on the initiation and up-titration of Guideline-Directed Medical Therapy (GDMT) in patients with heart failure (HF).
- Trial name
- NCT06580392
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Impulse Dynamics
Bradycardia, Atrial Tachyarrhythmia
AdvisaTM IPG Clinical Evaluation Study
The purpose of the Advisa IPG clinical study is to evaluate the overall system safety and clinical performance of the Advisa DR Implantable Pulse Generator (IPG).
- Trial name
- NCT00839384
- Testing
- Advisa IPG
- Where
- Czechia
- Volunteers
- 79 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
GLORIA-AF Registry Program (Phase I)
This study constitutes Phase I of the Registry Program. The main objective of this study is to characterize the newly diagnosed non-valvular AF patient population at risk for stroke and the selection of antithrombotic treatment…
- Trial name
- NCT01428765
- Where
- 62 sites in China, Croatia and 6 more
- Volunteers
- 1,096 people
- Sponsor
- Boehringer Ingelheim
Resuscitation, Cardiopulmonary
Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)
The purpose of this study is to test the possible neuroprotective effect of early high dose erythropoietin alpha after out of hospital cardiac arrest (OHCA).
- Conditions
- Resuscitation, Cardiopulmonary, Cardiac Arrest
- Trial name
- NCT00719498
- Testing
- Epo-alpha
- Volunteers
- 20 people
- Sponsor
- Janssen Cilag S.A.S.
Aortic Valve Disease, Aortic Valve Insufficiency
J-Valve Compassionate Use
J-Valve TF Compassionate Use cases approved on a case by case basis by the FDA
- Conditions
- Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Valve Stenosis
- Trial name
- NCT03876964
- Testing
- Transcatheter Aortic Valve Replacement
- Sponsor
- JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Heart Failure, NYHA Class III Heart Failure
NORM-HF Pivotal Study
This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF…
- Conditions
- Heart Failure, NYHA Class III Heart Failure, NYHA Class II Heart Failure
- Trial name
- NORM-HF (NCT07574593)
- Testing
- IVC Sensor
- Where
- 25 sites in United States
- Volunteers
- 800 people
- Sponsor
- Foundry Innovation & Research 1, Limited (FIRE1)
Heart Diseases
Lumason® Infusion vs. Bolus Administrations
A phase III study designed as a randomized, within-patient comparison of continuous infusion of diluted Lumason® versus the bolus administration of undiluted Lumason® for degree of LVO and assessment of LV EBD (co-primary…
- Trial name
- NCT06400004
- Testing
- Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON], Lumason
- Where
- 6 sites in United States
- Volunteers
- 106 people
- Sponsor
- Bracco Diagnostics, Inc
Heart Diseases
Video-Assisted Left Atrial Appendage Exclusion Trial
Exclusion of the LAA(Left Atrial Appendage) using the TigerPaw II System with VATS technique is safe and effective.
- Trial name
- VALET (NCT02226133)
- Testing
- LAAx, Inc. TigerPaw® System II
- Where
- 4 sites in United States
- Sponsor
- LAAx, Inc.
Right Heart Catheterization
The Nanowear Wearable System SimpleSense Validation Trial for Cardiac Output
The Nanowear SimpleSense study is a single center, prospective, non-randomized, feasibility, non- significant risk study The study will be done in 2 phases.
- Trial name
- NCT05629533
- Testing
- SimpleSense
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nanowear Inc.
Conduction Defect
Subcostal Temporary Extracardiac Pacing Study
Up to 15 subjects will be enrolled to evaluate initial safety and performance of the AtaCor Temporary Pacing System. Safety will be evaluated through analysis of all Adverse Events.
- Trial name
- STEP (NCT04096365)
- Testing
- Subcostal Temporary Extracardiac Pacing Lead
- Where
- Paraguay
- Volunteers
- 12 people
- Sponsor
- AtaCor Medical, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.